Mucosal corticosteroid therapy of IgA nephropathy.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 28709593.
- Also identified by DOI 10.1016/j.kint.2017.05.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The value of systemic immunosuppressive therapy for IgA nephropathy is uncertain. A recently completed randomized controlled phase II trial demonstrates that specially encapsulated budesonide, released preferentially in the terminal ileum, can reduce proteinuria and stabilize glomerular filtration rate in patients with IgA nephropathy.
Medical subject headings
- Budesonide
- Glomerulonephritis, IGA
- Glucocorticoids